![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Latest News
March 20, 2024
Posts
;
Great talk by @AndreaNecchi SURE-02 trial with SG/Pembro with impressive 44% cCR rate encouraging larger bladder preservation trials! Primary G-CSF prophylaxis key with SG!We are Working with @MonikaJoshimd on EA8231 @eaonc building on https://pubmed.ncbi.nlm.nih.gov/38261969/
#ASCO25 @OncoAlert
Excellent presentation by @NaomiHaas5 updates from KN564 trial with pembro vs placebo in resected RCC: significant DFS/OS benefit, consistent across subgroups, no new safety signal! Subsequent Tx were shown
@ASCO #ASCO25 @OncoAlert @TiansterZhang @montypal @eaonc @AndreaNecchi
@ASCO brings research to the forefront.
On Day 1 of #ASCO25, we’re highlighting the INDICATE trial, which explores genomic testing to guide post-surgery therapy decisions in prostate cancer.
Watch the IRB-approved video:
https://www.primrmed.com/cancer-clinical-trials/indicate-trial
@eaonc
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
37
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
